LEI: 549300Q7EXQQH6KF7Z84
14 May 2024
RTW Biotech Opportunities Ltd
Monthly Valuation Update and Factsheet
-9.7% NAV movement for the month
RTW Biotech Opportunities Ltd (the "Company") announces that the unaudited net asset value attributable to the ordinary shares of the Company at the close of business on 30 April 2024 (the "NAV") was US$591.7 million, or US$1.76 per ordinary share, -9.7% from the previous month.
The monthly factsheet is available on the Company's website:
https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/factsheets-letters/
Roderick Wong, M.D., Managing Partner and Chief Investment Officer of RTW Investments, said:
"No company specific events contributed materially in April. This was the worst month for the Russell 2000 Biotech Index since April 2022. Overall, the sector has given back the 20% gain since the Federal Reserve's dovish pivot on 14th December last year. This is despite the second largest biotech acquisition of 2023 (Bristol's $12.7B for Karuna) and continued leadership from obesity giants Lilly and Novo in the meantime. While we are never happy to give up gains, we are seeing ample opportunity despite the macro uncertainty. Over the medium term we strongly believe that cheap genetic information and the maturation of new modalities should continue to produce record numbers of new therapies, while Lilly and Novo's success should benefit the sector as a whole as they begin to redeploy their growing cash flows. We expect a busy year with an above average number of meaningful events. In addition, we are seeing a significant pipeline of private opportunities, including for creative dealmaking."
For Further Information
| RTW Investments, LP | +44 20 7959 6361 |
| Woody Stileman, Managing Director, Business Development Krisha McCune, Director, Investor Relations | |
|
Buchanan (PR & Communications Adviser) |
+44 20 7466 5107 |
| Charles Ryland |
|
| Henry Wilson |
|
| George Beale |
|
|
|
|
| Deutsche Numis (Joint Corporate Broker) | +44 20 7260 1000 |
| Freddie Barnfield |
|
| Nathan Brown |
|
| Euan Brown |
|
| |
|
| BofA Securities (Joint Corporate Broker) | +44 20 7628 1000 |
| Edward Peel |
|
| Alex Penney |
|
|
Cadarn Capital (Distribution & IR Partner) |
+44 73 6888 3211 |
| David Harris |
|
|
Elysium Fund Management Limited Joanna Duquemin Nicolle, Chief Executive Officer Sadie Morrison, Managing Director
|
+44 14 8181 0100 |
| Morgan Stanley Fund Services USA LLC | +1 914 225 8885 |
About Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.
***********
The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.
The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.
***********
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
